Efficacy and safety of tenecteplase administration in extended time window for acute ischemic stroke: An updated meta-analysis of randomized controlled trials

Эффективность и безопасность применения тенектеплазы в расширенном временно́м окне при остром ишемическом инсульте: обновлённый метаанализ рандомизированных контролируемых исследований
Moazzma Ifzaal, Sharib Afzal Bughio, Syed Ali Farhan Abbas Rizvi, Maryam Muzaffar, Rubia Ali, Moeen Ikram, Mohammed Murtaza, Agha Muhammad Wali Mirza, Hasaan Ans, Lavinia Bucataru, Armghan Haider Ans, Raheel Ahmed, Mushood Ahmed, Muhammad Ayyan, Muhammad Aemaz Ur Rehman
2025-05-03

acute ischemic strokeextended time windowrandomized controlled trialssymptomatic intracranial hemorrhagetenecteplase
BACKGROUND: Data regarding the efficacy and safety of tenecteplase (TNK) in patients with acute ischemic stroke (AIS) who present outside the standard treatment window are limited. This study aims to evaluate the role of TNK at a dose of 0.25 mg/kg, in treating AIS patients in an extended time window. METHODS: Searches were performed up to February 15, 2025 in PubMed, Embase, and Cochrane Library to include randomized-controlled trials (RCTs) comparing TNK (0.25 mg/kg) to no thrombolysis in AIS patients presenting after 4.5 hours of symptom onset or wake-up AIS. The primary efficacy outcomes included a 3-month excellent functional outcome (mRS ⩽1), and a good functional outcome (mRS ⩽2). Secondary safety outcomes assessed included symptomatic intracranial hemorrhage (sICH), any ICH, and 3-month all-cause death. A random-effects model was used to calculate summary estimates. RESULTS: 6 RCTs were included (n = 1,955 patients) in the meta-analysis. The pooled analysis demonstrated a significantly improved excellent functional outcome on 90 days (OR = 1.35, 95 % CI: 1.12 to 1.64) with TNK administration compared to control. No statistically significant association was observed for the two groups regarding good functional outcome (OR = 1.16, 95 % CI: 0.94 to 1.44), all-cause death (OR = 1.11, 95 % CI: 0.82 to 1.49), sICH (OR = 1.79, 95 % CI: 0.94 to 3.39), and any ICH (OR = 1.21, 95 % CI: 0.96 to 1.53). CONCLUSION: TNK administration in an extended time window for AIS patients leads to favorable neurological outcomes with a good safety profile.
1
An updated meta-analysis included 6 randomized controlled trials involving 1,955 acute ischemic stroke patients treated beyond 4.5 hours or after wake-up stroke.
2
No statistically significant differences were found for all-cause mortality, symptomatic intracranial hemorrhage, or any intracranial hemorrhage.
3
Tenecteplase at 0.25 mg/kg significantly increased the likelihood of excellent 90-day functional outcome (mRS ≤1) versus no thrombolysis (OR 1.35, 95% CI 1.12–1.64).
4
Tenecteplase was not significantly associated with good functional outcome defined as mRS ≤2 (OR 1.16, 95% CI 0.94–1.44).
5
The findings support favorable neurological outcomes and an overall good safety profile for tenecteplase in selected patients treated during an extended time window.

Acute ischemic stroke patients presenting in an extended time window or with wake-up stroke, treated with 0.25 mg/kg tenecteplase

The efficacy and safety of tenecteplase, including functional outcomes, symptomatic and any intracranial hemorrhage, and all-cause mortality

Publication Details
Publication Date
2025-05-03
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Moazzma Ifzaal
Sharib Afzal Bughio
Syed Ali Farhan Abbas Rizvi
Maryam Muzaffar
Rubia Ali
Moeen Ikram
Mohammed Murtaza
Agha Muhammad Wali Mirza
Hasaan Ans
Lavinia Bucataru
Armghan Haider Ans
Raheel Ahmed
Mushood Ahmed
Muhammad Ayyan
Muhammad Aemaz Ur Rehman
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%